Accenture Acquires Bionest To Expand Biopharma Focus

Accenture, among the most acquisitive companies in the IT solution provider business, has just closed on its third acquisition this year, Bionest, a provider of strategy and consulting to companies looking to expand their business in the life sciences market.

Global IT solution provider Accenture Thursday said it has acquired Bionest, a New York-based provider of strategy and consulting to customers in the life sciences industry.

The acquisition, the terms of which were not disclosed, brings to New York-based Accenture 46 science-focused consultants, executives, and specialists in the U.S. and Europe, Accenture said.

Bionest was founded in 2003 in Paris with an exclusive focus on working with businesses in the life sciences market, and in 2012 merged with New York-based Scisive Consulting.

[Related: Here Are Accenture’s 23 Acquisitions In 2022]

The company has expertise in biomarker testing, helping bring medical innovations to patients, helping bring cell and gene therapies to market, and improving the use of digital technology in life sciences value chains and product lifecycles.

Bionest will be a part of Accenture Strategy in the company’s life sciences practice.

Accenture, ranked No. 1 on the CRN 2022 Solution Provider 500 list, remains one of the most acquisitive companies in the IT space. Bionest is the company’s third acquisition it closed since January 1, following the purchases in January of European regulatory-focused consultant SKS Group and Bellevue, Wash.-based Oracle-focused digital supply chain consultant Inspirage.

Accenture executives were not available to provide more details by press time.

However, Brad Michel, Accenture senior managing director for North America Life Sciences practice, said in a statement that the Bionest team will be an important part of expanding Accenture’s biopharma business.

“Biopharma companies are shifting to New Science to drive more precise and effective ways to treat and care for patients in previously unattainable ways,” Michel said. “Oncology, precision medicine, and cell and gene therapies will drive disproportionate growth while delivering differentiated patient outcomes in the coming years. The addition of Bionest’s highly skilled team of experts expands our capabilities and will support our clients in bringing therapeutics to patients faster and more efficiently.”